Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
Other Sizes |
|
Cibinetide (ARA-290) is a novel 11-mer peptide and an EPO-derivative which acts as a specific agonist of erythropoietin/CD131 heteroreceptor with the potential to be used for treating neurological diseases.
ln Vitro |
Cibinetide (ARA290) promotes endothelial colony-forming cells' (ECFCs') motility, proliferation, and resistance against H2O2-induced apoptosis[1]. Cibinetide (ARA290) is an EPO-analog peptide that may have neurotrophic and depressive properties but has no hematological side effects[2].
|
|
---|---|---|
ln Vivo |
A single Cibinetide (ARA290) injection improves the hindlimb blood flow and capillary density after 28 days of ECFC transplantation in mice with CLI. It also improves the homing of radiolabeled transplanted cells to the ischemic leg 4 hours after transplantation[1]. Rats' body weight is unaffected by cipinetide (ARA290; 30 μg/kg, sc), which inhibits the increasing deterioration of glucose regulation. In GK rats, cipinetide dramatically lowers glucose AUCs in IPGTT[2]. Rats treated with low-dosage Cibinetide (35 μg/kg, ip) have just a small reduction in the severity of EAE. In a dose-dependent manner, the group receiving curenetide treatment (70 μg/kg, ip) considerably postpones the onset, reduces the neurologic severity, and shortens the duration of EAE[3].
|
|
Animal Protocol |
|
|
References |
[1]. Hache G, et al. ARA290, a Specific Agonist of Erythropoietin/CD131 Heteroreceptor, Improves Circulating Endothelial Progenitors' Angiogenic Potential and Homing Ability. Shock. 2016 Oct;46(4):390-7
[2]. Carole Muller, et al. ARA290 Improves Insulin Release and Glucose Tolerance in Type 2 Diabetic Goto-Kakizaki Rats. Mol Med. 2015; 21(1): 969–978 [3]. Chen H, et al. Therapeutic effects of nonerythropoietic erythropoietin analog ARA290 in experimental autoimmune encephalomyelitis rat. J Neuroimmunol. 2014 Mar 15;268(1-2):64-70 |
Molecular Formula |
C51H84N16O21
|
---|---|
Molecular Weight |
1257.32
|
Exact Mass |
1256.5997
|
CAS # |
1208243-50-8
|
Related CAS # |
1208243-50-8;Cibinetide acetate;
|
SMILES |
O=C([C@]([H])(C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])N([H])C([C@]([H])(C([H])([H])C([H])([H])C(N([H])[H])=O)N([H])C([C@]([H])(C([H])([H])C([H])([H])C(=O)O[H])N([H])C([C@]1([H])C([H])([H])C([H])([H])C(N1[H])=O)=O)=O)=O)N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@@]([H])(C([H])([H])[H])C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(N([H])[C@]([H])(C(=O)O[H])C([H])([H])O[H])=O)C([H])([H])O[H])=O)C([H])([H])C(N([H])[H])=O)=O)C([H])([H])C([H])(C([H])([H])[H])C([H])([H])[H])=O)=O)C([H])([H])C([H])([H])C([H])([H])/N=C(\N([H])[H])/N([H])[H])=O)C([H])([H])C([H])([H])C(=O)O[H]
|
Synonyms |
ARA-290 ARA 290 Cibinetide
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
H2O : ~66.67 mg/mL (~53.03 mM)
0.1 M NaOH :≥ 50 mg/mL (~39.77 mM) |
---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 2.5 mg/mL (1.99 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution.
 (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 0.7953 mL | 3.9767 mL | 7.9534 mL | |
5 mM | 0.1591 mL | 0.7953 mL | 1.5907 mL | |
10 mM | 0.0795 mL | 0.3977 mL | 0.7953 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.